Suchergebnisse - "Tuttle, Jay L"

PubPharm (15)

1

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance : Results From a Phase 2 Study

enthalten in: Clinical and translational gastroenterology | 2023

von Steere, B. | Schmitz, J. | Powell, N. | +10

2

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

enthalten in: Science translational medicine | 2022

von Benschop, R. | Tuttle, J. | Zhang, L. | +13

3

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease

enthalten in: Gastroenterology | 2022

von Sands, B. | Peyrin-Biroulet, L. | Kierkus, J. | +12

4

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Sandborn, W. | Ferrante, M. | Bhandari, B. | +11

5

The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination

enthalten in: bioRxiv.org | 2021

von Benschop, R. | Tuttle, J. | Zhang, L. | +13

6

Innovative clinical trial design and delivery : a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)

enthalten in: Trials | 2021

von Knorr, J. | Tuttle, J. | Sabo, J. | +3

7

Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2)

enthalten in: Trials | 2021

von Knorr, J. | Tuttle, J. | Sabo, J. | +3

8

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities : A Randomized Clinical Trial

enthalten in: JAMA | 2021

von Cohen, M. | Nirula, A. | Mulligan, M. | +52

CommentIn: JAMA. 2021 Jul 6;326(1):31-32. - PMID 34081075

9

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

enthalten in: Gastroenterology | 2020

von Sandborn, W. | Ferrante, M. | Bhandari, B. | +11

CommentIn: Gastroenterology. 2020 Feb;158(3):467-470. - PMID 31862200

10

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

enthalten in: Journal of hematology & oncology | 2017

von Vadhan-Raj, S. | Abonour, R. | Goldman, J. | +10